• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Enveric Biosciences Inc (NQ: ENVB )

    0.5416 -0.0382 (-6.59%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Aug 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 302,762
    Open 0.5700
    Bid (Size) 0.5400 (21)
    Ask (Size) 0.5600 (2)
    Prev. Close 0.5798
    Today's Range 0.5305 - 0.5790
    52wk Range 0.4100 - 2.920
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
    From Enveric Biosciences
    Via Business Wire
    ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024
    ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -57.02%
    -57.02%
    1 Month
    +16.22%
    +16.22%
    3 Month
    -34.59%
    -34.59%
    6 Month
    -37.45%
    -37.45%
    1 Year
    -76.55%
    -76.55%

    More News

    Read More
    Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
    From Enveric Biosciences
    Via Business Wire
    Why Is Imunon (IMNN) Stock Up 259% Today?
    Via InvestorPlace
    Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?
    Via InvestorPlace
    Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Why Is Ekso Bionics (EKSO) Stock Down 15% Today?
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally
    Via Benzinga
    Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
    From Enveric Biosciences
    Via Business Wire
    Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
    From Enveric Biosciences
    Via Business Wire
    New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Enveric Biosciences Announces Patent Granted for Drug Candidate
    From Enveric Biosciences
    Via Business Wire
    Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
    From Enveric Biosciences
    Via Business Wire
    Enveric Biosciences to Participate in BIO International Convention 2024
    From Enveric Biosciences
    Via Business Wire
    ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024
    Via InvestorPlace
    'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand
    Via Benzinga
    Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
    From Enveric Biosciences
    Via Business Wire
    Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
    Via Benzinga
    Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
    From Enveric Biosciences
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
    From Enveric Biosciences
    Via Business Wire
    Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.